middle.news
Noxopharm and InhaTarget Demonstrate 77% Lung Inflammation Reduction with Sofra Inhalation
8:46am on Monday 27th of April, 2026 AEST
•
Biotechnology
Read Story
Noxopharm and InhaTarget Demonstrate 77% Lung Inflammation Reduction with Sofra Inhalation
8:46am on Monday 27th of April, 2026 AEST
Key Points
Sofra oligonucleotides reduce lung inflammation by over 75% in mice
InhaTarget’s lipid nanoparticle inhalation system enables targeted pulmonary delivery
Collaboration expands Sofra platform into lung diseases with novel delivery
Results build on Sofra’s growing pipeline and delivery partnerships
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE